Cerus Endovascular Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $525M

  • Investors
  • 1

Cerus Endovascular General Information

Description

Developer of proprietary interventional neuroradiology devices designed to support the treatment of neurovascular diseases. The company's neuroradiology devices are used for the treatment of hemorrhagic strokes and a range of aneurysm morphologies, including unruptured wide-necked bifurcation and bifurcation aneurysms, thereby enabling interventional neuroradiologists to treat minimally invasive neurovascular diseases, particularly intracranial aneurysms.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • John Eccles House
  • Oxford Science Park
  • Oxford OX4 4GP
  • England, United Kingdom
+44 051
Primary Industry
Therapeutic Devices
Other Industries
Diagnostic Equipment
Parent Company
Vertical(s)
Corporate Office
  • John Eccles House
  • Oxford Science Park
  • Oxford OX4 4GP
  • England, United Kingdom
+44 051

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cerus Endovascular Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 01-May-2023 $525M Completed Generating Revenue
6. Later Stage VC (Series B) 21-Feb-2020 Completed Generating Revenue
5. Later Stage VC 21-Jul-2016 Completed Generating Revenue
4. Early Stage VC 30-Jun-2015 Completed Generating Revenue
3. Early Stage VC Completed Generating Revenue
2. Early Stage VC (Series A) 03-May-2013 $3M $3M Completed Generating Revenue
1. University Spin-Out 01-Jan-2011 Completed Startup
To view Cerus Endovascular’s complete valuation and funding history, request access »

Cerus Endovascular Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary 33,789 $0.000065 $77.35 $77.35 1x $77.35 5.45%
Series A 140,388 $0.000065 $19.53 $19.53 1x $19.53 22.66%
To view Cerus Endovascular’s complete cap table history, request access »

Cerus Endovascular Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of proprietary interventional neuroradiology devices designed to support the treatment of neurovascular diseas
Therapeutic Devices
Oxford, United Kingdom
12 As of 2023

Amersfoort, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cerus Endovascular Competitors (1)

One of Cerus Endovascular’s competitors is AngioCare, a Corporate Backed or Acquired company based in Amersfoort, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AngioCare Corporate Backed or Acquired Amersfoort, Netherlands
You’re viewing 1 of 1 competitors. Get the full list »

Cerus Endovascular Patents

Cerus Endovascular Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3168316-A1 Clot removal distal protection methods Pending 20-Feb-2020
CA-3073232-A1 Occlusion device Active 21-Aug-2017
CA-3073232-C Occlusion device Active 21-Aug-2017
ES-2971315-T3 Occlusion device Active 21-Aug-2017
CA-3016679-A1 Occlusion device Pending 11-Mar-2016 A61B17/12122
To view Cerus Endovascular’s complete patent history, request access »

Cerus Endovascular Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cerus Endovascular Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andover Ventures Venture Capital Minority
Epiphany Capital Venture Capital Minority
Innovate UK Government Minority
Angel (individual) Minority
Johnston Associates Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Cerus Endovascular FAQs

  • When was Cerus Endovascular founded?

    Cerus Endovascular was founded in 2011.

  • Where is Cerus Endovascular headquartered?

    Cerus Endovascular is headquartered in Oxford, United Kingdom.

  • What is the size of Cerus Endovascular?

    Cerus Endovascular has 12 total employees.

  • What industry is Cerus Endovascular in?

    Cerus Endovascular’s primary industry is Therapeutic Devices.

  • Is Cerus Endovascular a private or public company?

    Cerus Endovascular is a Private company.

  • What is the current valuation of Cerus Endovascular?

    The current valuation of Cerus Endovascular is .

  • What is Cerus Endovascular’s current revenue?

    The current revenue for Cerus Endovascular is .

  • How much funding has Cerus Endovascular raised over time?

    Cerus Endovascular has raised $37.3M.

  • Who are Cerus Endovascular’s investors?

    Andover Ventures, Epiphany Capital, Innovate UK, , and Johnston Associates are 5 of 8 investors who have invested in Cerus Endovascular.

  • Who are Cerus Endovascular’s competitors?

    AngioCare is a competitor of Cerus Endovascular.

  • When was Cerus Endovascular acquired?

    Cerus Endovascular was acquired on 01-May-2023.

  • Who acquired Cerus Endovascular?

    Cerus Endovascular was acquired by Stryker.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »